




Spectrum Pharmaceuticals, Inc.  
Investor Relations Department  
157 Technology Drive  
Irvine, CA 92618  
United States

Visit IR website   
Sign-up for email alerts 

#### NASDAQ: SPPI <sup>1</sup>

Last Trade:	18.59
Trade Time:	10:53 AM ET Dec 15, 2017
Change:	-0.07  (0.375%)
Day Range	18.31 - 18.70
52-Week Range	4.21 - 21.95
Volume	237,453
Market Cap. (\$M)	1,871.269
Shares Out (M)	100.660

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncology and Hematology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy.

Spectrum Pharmaceuticals' stock is traded through the Nasdaq Global Market System.

Ticker Symbol: [SPPI](#)

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Dec 13, 2017  
[Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® \(pralatrexate injection\) at the 59th Annual Meeting of the American Society of Hematology \(ASH\)](#)

Dec 4, 2017  
[Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology \(ASH\) in Atlanta, Georgia, December 9-12, 2017](#)

Nov 8, 2017  
[Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th](#)

Nov 2, 2017  
[Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update](#)

Oct 30, 2017  
[Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer \(NSCLC\) Patients with Exon 20 Insertion Mutation in EGFR or HER2](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Third Quarter Financial Results](#)

Mar 14, 2017  
[Annual Report \(10-K\)](#)

Apr 17, 2017  
[Definitive Proxy Statement](#)

Nov 3, 2017  
[Quarterly Report \(10-Q\)](#)

Aug 4, 2017  
[Quarterly Report \(10-Q\)](#)

May 4, 2017  
[Quarterly Report \(10-Q\)](#)

